NDAORALTABLETPriority Review
Approved
Nov 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
CYTOXAN (cyclophosphamide) by Baxter is cross-linking of tumor cell dna. Approved for breast cancer, lymphoma, leukemia and 4 more indications. First approved in 1959.
Drug data last refreshed 20h ago
Mechanism of Action
cross-linking of tumor cell DNA.
Indications (7)
Worked on CYTOXAN at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.